AZ, Lilly pull plug on Alzheimer’s disease trials
Alzheimer’s disease research has taken another hit with the failure of AstraZeneca and Eli Lilly’s experimental BACE inhibitor lanabecestat.
Read More
Tag: BACE inhibitor
Eisai, Biogen move Alzheimer’s drug into Phase III
Eisai and Biogen have had confirmation from US regulators that they can progress their BACE inhibitor E2609 into Phase III clinical trials to test its safety and efficacy in Alzheimer’s disease.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
